| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Valeo Pharma Inc (OTCQB: VPHIF)
VPHIF Technical Analysis
5
| As on 25th Dec 2024 VPHIF STOCK Price closed @ 0.05 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.19 & Strong Sell for SHORT-TERM with Stoploss of 0.29 we also expect STOCK to react on Following IMPORTANT LEVELS. |
VPHIFSTOCK Price
| Open | 0.12 | Change | Price | % |
| High | 0.12 | 1 Day | 0.00 | 0.00 |
| Low | 0.05 | 1 Week | -0.07 | -58.33 |
| Close | 0.05 | 1 Month | 0.00 | 0.00 |
| Volume | 4500 | 1 Year | -0.27 | -84.38 |
| 52 Week High 0.43 | 52 Week Low 0.03 | ||||
OTCQB USA Most Active Stocks
| FNMA | 4.98 | 9.69% |
| BMIX | 0.01 | % |
| BTCWF | 0.10 | 150.00% |
| FMCC | 4.94 | 12.53% |
| INVU | 0.02 | 100.00% |
| ALPP | 3.56 | 0.00% |
| ALPP | 3.56 | 0.00% |
| CBDS | 0.06 | -25.00% |
| VKIN | 0.23 | 0.00% |
| SRNA | 2.78 | 14.88% |
OTCQB USA Top Gainers Stocks
OTCQB USA Top Losers Stocks
| VPHIF Daily Charts |
VPHIF Intraday Charts |
Whats New @ Bazaartrend |
VPHIF Free Analysis |
|
|
VPHIF Important Levels Intraday
| RESISTANCE | 0.18 |
| RESISTANCE | 0.14 |
| RESISTANCE | 0.11 |
| RESISTANCE | 0.09 |
| SUPPORT | 0.01 |
| SUPPORT | -0.01 |
| SUPPORT | -0.04 |
| SUPPORT | -0.08 |
VPHIF Forecast May 2025
| 4th UP Forecast | 0.44 |
| 3rd UP Forecast | 0.31 |
| 2nd UP Forecast | 0.24 |
| 1st UP Forecast | 0.16 |
| 1st DOWN Forecast | -0.06 |
| 2nd DOWN Forecast | -0.14 |
| 3rd DOWN Forecast | -0.21 |
| 4th DOWN Forecast | -0.34 |
VPHIF Weekly Forecast
| 4th UP Forecast | 0.45 |
| 3rd UP Forecast | 0.32 |
| 2nd UP Forecast | 0.24 |
| 1st UP Forecast | 0.16 |
| 1st DOWN Forecast | -0.06 |
| 2nd DOWN Forecast | -0.14 |
| 3rd DOWN Forecast | -0.22 |
| 4th DOWN Forecast | -0.35 |
VPHIF Forecast2025
| 4th UP Forecast | 0.86 |
| 3rd UP Forecast | 0.6 |
| 2nd UP Forecast | 0.44 |
| 1st UP Forecast | 0.28 |
| 1st DOWN Forecast | -0.18 |
| 2nd DOWN Forecast | -0.34 |
| 3rd DOWN Forecast | -0.5 |
| 4th DOWN Forecast | -0.76 |
Valeo Pharma Inc ( OTCQB USA Symbol : VPHIF )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
VPHIF Business Profile
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing, and commercialization of pharmaceutical products with a primary focus on neurodegenerative diseases, oncology and supportive care, and hospital products. Its products portfolio includes Redesca, a low molecular weight heparin (LMWH) biosimilar to treat and prevent deep vein thrombosis and pulmonary embolism; Hesperco, a capsule that supports the immune system; Onstryv, an oral medication for Parkinson's disease; M-Eslon, a narcotic analgesic for pain management; and Ametop Gel, a tetracaine hydrochloride gel for the percutaneous anesthetic to produce anesthesia of the skin prior to venepuncture or venous cannulation. The company also provides Ethacrynate Sodium, a loop diuretic used to treat high blood pressure and the swelling caused by diseases, such as congestive heart failure, liver failure, and kidney failure; Synacthen Depot, a synthetic adrenocorticotropic hormone to treat multiple sclerosis and nephrotic syndrome; Ondansetron for the prevention of nausea and vomiting caused by cancer chemotherapy; Benztropine, an anticholinergic agent used for the treatment of Parkinson's disease; and Yondelis, a novel marine-derived antitumor agent for the treatment of patients with metastatic liposarcoma or leiomyosarcoma after failure of prior anthracycline and ifosfamide chemotherapy. In addition, its product pipeline includes Piperacillin/tazobactam, an injectable antibiotic, as well as various hospital products for anti-fungal, antibiotic, pain management, and other indications. The company was incorporated in 2003 and is headquartered in Kirkland, Canada. Address: 16667 Hymus Boulevard, Kirkland, QC, Canada, H9H 4R9
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service